Two phase III trials comparing nivolumab versus TMZ, each in combination with RT, in patients with newly diagnosed MGMT-unmethylated glioblastoma (CheckMate-498, NCT02617589) and TMZ plus RT combined with nivolumab or placebo in patients with newly diagnosed MGMT-methylated glioblastoma (CheckMate-548, NCT02667587) are ongoing. Here, MGMT is linked to glioblastoma.